Therapeutic hypothermia for acute ischaemic stroke: Results of a European multicentre, randomised, phase III clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • H Bart van der Worp
  • Malcolm R Macleod
  • Philip Mw Bath
  • Raj Bathula
  • Christensen, Hanne Krarup
  • Bridget Colam
  • Charlotte Cordonnier
  • Jacques Demotes-Mainard
  • Isabelle Durand-Zaleski
  • Christian Gluud
  • Janus Christian Jakobsen
  • Bernd Kallmünzer
  • Rainer Kollmar
  • Derk W Krieger
  • Kennedy R Lees
  • Dominik Michalski
  • Carlos Molina
  • Joan Montaner
  • Risto O Roine
  • Jesper Petersson
  • Richard Perry
  • Nikola Sprigg
  • Dimitre Staykov
  • Istvan Szabo
  • Geert Vanhooren
  • Joanna M Wardlaw
  • Per Winkel
  • Stefan Schwab
  • EuroHYP-1 investigators

Introduction: We assessed whether modest systemic cooling started within 6 hours of symptom onset improves functional outcome at three months in awake patients with acute ischaemic stroke.

Patients and methods: In this European randomised open-label clinical trial with blinded outcome assessment, adult patients with acute ischaemic stroke were randomised to cooling to a target body temperature of 34.0-35.0°C, started within 6 h after stroke onset and maintained for 12 or 24 h , versus standard treatment. The primary outcome was the score on the modified Rankin Scale at 91 days, as analysed with ordinal logistic regression.

Results: The trial was stopped after inclusion of 98 of the originally intended 1500 patients because of slow recruitment and cessation of funding. Forty-nine patients were randomised to hypothermia versus 49 to standard treatment. Four patients were lost to follow-up. Of patients randomised to hypothermia, 15 (31%) achieved the predefined cooling targets. The primary outcome did not differ between the groups (odds ratio for good outcome, 1.01; 95% confidence interval, 0.48-2.13; p = 0.97). The number of patients with one or more serious adverse events did not differ between groups (relative risk, 1.22; 95% confidence interval, 0.65-1.94; p = 0.52).

Discussion: In this trial, cooling to a target of 34.0-35.0°C and maintaining this for 12 or 24 h was not feasible in the majority of patients. The final sample was underpowered to detect clinically relevant differences in outcomes.

Conclusion: Before new trials are launched, the feasibility of cooling needs to be improved.

OriginalsprogEngelsk
TidsskriftEuropean Stroke Journal
Vol/bind4
Udgave nummer3
Sider (fra-til)254-262
ISSN2396-9873
DOI
StatusUdgivet - 2019

Bibliografisk note

© European Stroke Organisation 2019.

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 240531939